The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
AstraZeneca Pharma India discontinues manufacturing of Imdur
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Subscribe To Our Newsletter & Stay Updated
